1. Home
  2. BTTC vs RNTX Comparison

BTTC vs RNTX Comparison

Compare BTTC & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BTTC
  • RNTX
  • Stock Information
  • Founded
  • BTTC 1990
  • RNTX 2001
  • Country
  • BTTC Malaysia
  • RNTX United States
  • Employees
  • BTTC N/A
  • RNTX N/A
  • Industry
  • BTTC Biotechnology: Biological Products (No Diagnostic Substances)
  • RNTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • BTTC Health Care
  • RNTX Health Care
  • Exchange
  • BTTC Nasdaq
  • RNTX Nasdaq
  • Market Cap
  • BTTC 40.5M
  • RNTX 34.6M
  • IPO Year
  • BTTC N/A
  • RNTX N/A
  • Fundamental
  • Price
  • BTTC $4.36
  • RNTX $1.52
  • Analyst Decision
  • BTTC
  • RNTX Buy
  • Analyst Count
  • BTTC 0
  • RNTX 2
  • Target Price
  • BTTC N/A
  • RNTX $10.00
  • AVG Volume (30 Days)
  • BTTC 652.6K
  • RNTX 114.1K
  • Earning Date
  • BTTC 01-01-0001
  • RNTX 11-13-2025
  • Dividend Yield
  • BTTC N/A
  • RNTX N/A
  • EPS Growth
  • BTTC N/A
  • RNTX N/A
  • EPS
  • BTTC N/A
  • RNTX N/A
  • Revenue
  • BTTC N/A
  • RNTX N/A
  • Revenue This Year
  • BTTC N/A
  • RNTX N/A
  • Revenue Next Year
  • BTTC N/A
  • RNTX N/A
  • P/E Ratio
  • BTTC N/A
  • RNTX N/A
  • Revenue Growth
  • BTTC N/A
  • RNTX N/A
  • 52 Week Low
  • BTTC $4.00
  • RNTX $1.04
  • 52 Week High
  • BTTC $39.00
  • RNTX $4.40
  • Technical
  • Relative Strength Index (RSI)
  • BTTC N/A
  • RNTX 64.70
  • Support Level
  • BTTC N/A
  • RNTX $1.22
  • Resistance Level
  • BTTC N/A
  • RNTX $1.30
  • Average True Range (ATR)
  • BTTC 0.00
  • RNTX 0.08
  • MACD
  • BTTC 0.00
  • RNTX 0.02
  • Stochastic Oscillator
  • BTTC 0.00
  • RNTX 100.00

About BTTC Black Titan Corporation Ordinary Shares

Black Titan Corp is engaged in software implementation and training. It provides consulting services and Human Resource and Payroll solutions.

About RNTX Rein Therapeutics Inc. Common Stock

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: